

The following protocol information is provided solely to describe how the authors conducted the research underlying the published report associated with the following article:

SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer.

Budd, et al

DOI: 10.1200/JCO.2014.56.3296

The information provided may not reflect the complete protocol or any previous amendments or modifications. As described in the Information for Contributors (<http://jco.ascopubs.org/site/ifc/protocol.xhtml>) only specific elements of the most recent version of the protocol are requested by JCO. The protocol information is not intended to replace good clinical judgment in selecting appropriate therapy and in determining drug doses, schedules, and dose modifications. The treating physician or other health care provider is responsible for determining the best treatment for the patient. ASCO and JCO assume no responsibility for any injury or damage to persons or property arising out of the use of these protocol materials or due to any errors or omissions. Individuals seeking additional information about the protocol are encouraged to consult with the corresponding author directly.

Supplementary Appendix

Figure S1a. Kaplan-Meier disease-free survival by randomized arm for patients with HER2-positive tumors.




Figure S1b. Kaplan-Meier overall survival by randomized arm for patients with Hormone Receptor-negative, HER2-negative tumors.




Figure S1c. Kaplan-Meier overall survival by randomized arm for patients with Hormone Receptor-Positive, HER2-negative tumors.




Figure S1d. Kaplan-Meier overall survival by randomized arm for patients with HER2-positive tumors.




Table 2 DFS and OS Outcomes by Breast Cancer Biology

	<b>Overall trial</b> n = 2,667	<b>HR-positive; HER2-negative</b> n = 1,481	<b>HR-negative; HER2-negative</b> n = 681	<b>HER2-positive</b> n = 475
<b>Disease-Free Survival</b>				
<b>Events</b>	550	270	186	87
<b>Event rate per year</b>	0.0389	0.0334	0.0545	0.0352
<b>Overall treatment differences</b>	p = 0.104	p = 0.67	p = 0.076	p = 0.69
<b>Interaction of AC and paclitaxel</b>	p = 0.024	p = 0.42	p = 0.018	p = 0.66
<b>5-year survival estimates</b>				
<b>All arms</b>	81% (80%-83%)	84% (82%-86%)	75% (71%-78%)	83% (79%-86%)
<b>Arm 1</b>	83% (80%-86%)	82% (78%-86%)	83% (75%-88%)	85% (77%-90%)
<b>Arm 2</b>	79% (76%-82%)	82% (77%-86%)	71% (63%-77%)	83% (74%-89%)
<b>Arm 3</b>	81% (78%-84%)	86% (82%-89%)	72% (64%-78%)	82% (74%-88%)
<b>Arm 4</b>	81% (78%-84%)	85% (80%-88%)	75% (68%-81%)	80% (71%-87%)
<b>Overall Survival</b>				
<b>Events</b>	387	185	139	56
<b>Event rate per year</b>	0.0260	0.0218	0.0382	0.0214
<b>Overall treatment differences</b>	p = 0.035	p = 0.90	p = 0.062	p = 0.40
<b>Interaction of AC and paclitaxel</b>	p = 0.010	p = 0.52	p = 0.010	p = 0.28
<b>5-year survival estimates</b>				
<b>All arms</b>	88% (87%-89%)	91% (89%-92%)	80% (77%-83%)	90% (87%-93%)
<b>Arm 1</b>	90% (87%-92%)	91% (87%-93%)	85% (78%-90%)	94% (88%-97%)
<b>Arm 2</b>	87% (84%-90%)	92% (89%-95%)	76% (69%-82%)	89% (81%-94%)
<b>Arm 3</b>	87% (84%-89%)	91% (87%-94%)	78% (71%-84%)	89% (82%-94%)
<b>Arm 4</b>	87% (84%-90%)	90% (86%-93%)	82% (75%-87%)	88% (80%-93%)